---
input_text: "Effect of chelation therapy in pediatric Wilson's disease: Liver and
  endoscopic outcome. BACKGROUND: As there is paucity of exclusive literature on pediatric
  hepatic Wilson's disease (WD), this study was undertaken to evaluate the efficacy
  of chelation on hepatocellular function and portal hypertension in WD. METHODS:
  Wilson's disease patients with >=9 months of follow-up were evaluated for response
  to chelation therapy in the following categories: (a) complete remission, (b) partial
  remission (c) progression of disease; (d) drug toxicity. Pediatric end-stage liver
  disease (PELD), Nazar and New Wilson Index scores were compared. Hemodynamically
  stable patients underwent esophagogastroduodenoscopy (baseline and surveillance)
  and received prophylaxis (primary or secondary). Endoscopic outcome was assessed
  at follow-up. RESULTS: Of the 111 WD children (aged 9 [3-15] years; PELD score 16
  [-11 to 60]), 65 with follow-up of 3.6 (0.8-12) years on chelation (83% D-penicillamine
  monotherapy, 17% D-penicillamine and zinc) were analyzed. 81% had severe disease
  at presentation. Favorable outcome (complete and or partial remission), progression
  of disease and drug toxicity were seen in 71%, 29% and 10.8%, respectively. Two-thirds
  had esophageal varices which did not show progression. Large esophageal varices
  (16%) were effectively downgraded in 3 (2-6) therapeutic endoscopic sessions. Nazar
  score and PELD score at baseline were independent predictors of outcome with favorable
  correlation with each other (r = .864, P < .001). PELD cutoff 9.45 (AUC: 71%, sensitivity:
  87%, specificity: 50%; P = .009) and Nazar score cut off 3.5 (AUC: 68%, sensitivity:
  83%, specificity: 50%; P = .02) were associated with poor prognosis. CONCLUSIONS:
  Despite severe liver disease, the majority of hepatic WD can be managed on D-penicillamine
  monotherapy. PELD score and Nazar score effectively determine the outcome."
raw_completion_output: |-
  primary_disease: Wilson's disease

  medical_actions: chelation therapy; prophylaxis; therapeutic endoscopic sessions; D-penicillamine monotherapy

  symptoms: hepatocellular function impairment; portal hypertension; esophageal varices

  chemicals: D-penicillamine; zinc

  action_annotation_relationships: chelation therapy TREATS hepatocellular function impairment IN Wilson's disease; chelation therapy TREATS portal hypertension IN Wilson's disease; prophylaxis PREVENTS progression of esophageal varices IN Wilson's disease; therapeutic endoscopic sessions TREATS esophageal varices IN Wilson's disease; D-penicillamine monotherapy (with D-penicillamine) TREATS hepatocellular function impairment IN Wilson's disease; D-penicillamine monotherapy (with D-penicillamine) TREATS portal hypertension IN Wilson's disease
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  D-penicillamine monotherapy (with D-penicillamine) TREATS portal hypertension IN Wilson's disease

  ===

extracted_object:
  primary_disease: MONDO:0010200
  medical_actions:
    - chelation therapy
    - prophylaxis
    - therapeutic endoscopic sessions
    - D-penicillamine monotherapy
  symptoms:
    - hepatocellular function impairment
    - HP:0001409
    - HP:0002040
  chemicals:
    - CHEBI:7959
    - CHEBI:27363
  action_annotation_relationships:
    - subject: chelation therapy
      predicate: TREATS
      object: hepatocellular function impairment
      qualifier: MONDO:0010200
      subject_extension: chelation therapy
    - subject: chelation therapy
      predicate: TREATS
      object: HP:0001409
      qualifier: MONDO:0010200
    - subject: prophylaxis
      predicate: PREVENTS
      object: progression of esophageal varices
      qualifier: MONDO:0010200
    - subject: therapeutic endoscopic sessions
      predicate: TREATS
      object: HP:0002040
      qualifier: MONDO:0010200
    - subject: monotherapy
      predicate: TREATS
      object: hepatocellular function impairment
      qualifier: MONDO:0010200
      subject_qualifier: with D-penicillamine
      subject_extension: CHEBI:7959
    - subject: monotherapy
      predicate: TREATS
      object: HP:0001409
      qualifier: MONDO:0010200
      subject_qualifier: with D-penicillamine
      subject_extension: CHEBI:7959
named_entities:
  - id: MONDO:0010200
    label: Wilson's disease
  - id: MAXO:0001175
    label: liver transplantation
  - id: HP:0001695
    label: cardiac arrest
  - id: HP:0001685
    label: myocardial fibrosis
  - id: HP:0001663
    label: ventricular fibrillation
  - id: CHEBI:30703
    label: tetrathiomolybdate (TTM)
  - id: CHEBI:35176
    label: Zinc sulphate
  - id: CHEBI:35475
    label: NSAIDs
  - id: MAXO:0001001
    label: Gene therapy
  - id: HP:0006554
    label: acute liver failure
  - id: HP:0003256
    label: coagulopathy
  - id: HP:0002480
    label: hepatic encephalopathy
  - id: HP:0001337
    label: Tremor
  - id: HP:0001332
    label: Dystonia
  - id: CHEBI:28694
    label: Copper
  - id: HP:0001395
    label: Liver fibrosis
  - id: HP:0001394
    label: Cirrhosis
  - id: CHEBI:39501
    label: trientine
  - id: CHEBI:27363
    label: zinc
  - id: HP:0001410
    label: hepatic dysfunction
  - id: CHEBI:7959
    label: D-penicillamine
  - id: MAXO:0000376
    label: Liver biopsy
  - id: HP:0001404
    label: Hepatocellular necrosis
  - id: CHEBI:61049
    label: Tacrolimus
  - id: CHEBI:50868
    label: Penicillamine
  - id: HP:0001744
    label: splenomegaly
  - id: HP:0001541
    label: ascites
  - id: HP:0001260
    label: Dysarthria
  - id: HP:0001347
    label: Hyperreflexia
  - id: HP:0031843
    label: Bradyphrenia
  - id: HP:0002362
    label: Shuffling gait
  - id: HP:0002300
    label: Mutism
  - id: HP:0001621
    label: Hypophonia
  - id: CHEBI:37153
    label: Calcineurin inhibitors
  - id: CHEBI:8356
    label: Pramipexole
  - id: CHEBI:2618
    label: Amantadine
  - id: HP:0001399
    label: liver failure
  - id: HP:0000952
    label: jaundice
  - id: HP:0001919
    label: acute kidney injury
  - id: HP:0200032
    label: Kayser-Fleischer rings
  - id: MONDO:0013792
    label: Intracerebral Hemorrhage
  - id: HP:0001342
    label: Intracerebral Hemorrhage
  - id: MAXO:0000533
    label: Molecular genetic testing
  - id: HP:0001873
    label: thrombocytopenia
  - id: HP:0002344
    label: worsening neurological symptoms
  - id: HP:0001272
    label: Cerebellar Atrophy
  - id: HP:0012896
    label: abnormal motor evoked potentials (MEPs)
  - id: HP:0001392
    label: liver disease
  - id: HP:0001396
    label: cholestasis
  - id: HP:0001403
    label: macrovesicular steatosis
  - id: CHEBI:8830
    label: rhodanine
  - id: CHEBI:90299
    label: orcein
  - id: MONDO:0018874
    label: Acute Myeloid Leukemia (t-AML or AML-MRC)
  - id: CHEBI:41977
    label: Daunorubicin
  - id: CHEBI:28680
    label: Cytarabine
  - id: CHEBI:37404
    label: Elemental copper
  - id: CHEBI:16856
    label: Plasma glutathione (GSH)
  - id: CHEBI:53498
    label: Total antioxidant capacity (TAC)
  - id: CHEBI:566274
    label: Malondialdehyde (MDA)
  - id: CHEBI:33697
    label: RNAs
  - id: HP:0000989
    label: itchy skin
  - id: CHEBI:63623
    label: Dimercaptosuccinic acid
  - id: CHEBI:145810
    label: insulin
  - id: HP:0001250
    label: Epileptic seizures
  - id: HP:0001298
    label: Encephalopathy
  - id: HP:0002315
    label: Headache
  - id: CHEBI:6437
    label: Levetiracetam
  - id: HP:0002878
    label: Acute respiratory failure
  - id: CHEBI:166831
    label: copper chelating agents
  - id: MONDO:0004789
    label: Cholangitis
  - id: MAXO:0010026
    label: zinc supplementation
  - id: CHEBI:16796
    label: Melatonin
  - id: MAXO:0009095
    label: Zinc (Zn) therapy
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:38161
    label: Chelator
  - id: MONDO:0019542
    label: Acute Liver Failure (ALF)
  - id: HP:0002204
    label: Pulmonary embolism
  - id: HP:0100806
    label: Sepsis
  - id: HP:0001944
    label: dehydration
  - id: CHEBI:18248
    label: iron
  - id: CHEBI:18291
    label: manganese
  - id: CHEBI:22984
    label: calcium
  - id: HP:0001081
    label: Cholelithiasis
  - id: HP:0002716
    label: Lymphadenopathy
  - id: MONDO:0100193
    label: End-stage liver diseases
  - id: HP:0002040
    label: Esophageal varices
  - id: HP:0100626
    label: End-stage liver diseases
  - id: MONDO:0017014
    label: children
  - id: MAXO:0009016
    label: Botulinum toxin type A (BoNT-A) injection
  - id: CHEBI:3160
    label: Botulinum toxin type A (BoNT-A)
  - id: HP:0003088
    label: Premature osteoarthritis
  - id: HP:0002885
    label: Mallory-Denk body (MDB) formation
  - id: CHEBI:35341
    label: Steroids
  - id: CHEBI:16990
    label: Bilirubin
  - id: MONDO:0100192
    label: Liver failure
  - id: HP:0001409
    label: Portal hypertension
  - id: HP:0001402
    label: Hepatocellular carcinoma
  - id: CHEBI:30663
    label: Serum ceruloplasmin (CP)
  - id: HP:0001513
    label: obesity
  - id: CHEBI:16610
    label: spermidine
  - id: CHEBI:27881
    label: resveratrol
  - id: CHEBI:15351
    label: AcCoA
  - id: HP:0001300
    label: Parkinsonism
  - id: CHEBI:62984
    label: zinc acetate
  - id: MAXO:0000165
    label: treatment with diuretics
  - id: CHEBI:35498
    label: diuretics
  - id: CHEBI:33281
    label: antibiotics
  - id: CHEBI:50503
    label: laxatives
  - id: CHEBI:76649
    label: Aspartate aminotransferase (AST)
  - id: CHEBI:37708
    label: Alanine aminotransferase (ALT)
  - id: HP:0011967
    label: Copper deficiency
  - id: CHEBI:38127
    label: Thiocarbamate
  - id: CHEBI:25548
    label: Nitrilotriacetate
  - id: CHEBI:16494
    label: Lipoic acid
  - id: MONDO:0010651
    label: Menkes disease
  - id: MAXO:0000127
    label: genetic testing
  - id: CHEBI:64357
    label: rituximab
  - id: CHEBI:18132
    label: CHOP
  - id: HP:0002665
    label: lymphoma
  - id: MONDO:0005395
    label: Movement disorders
  - id: MAXO:0000526
    label: Clinical examination
  - id: MAXO:0000427
    label: Brain MRI
  - id: MAXO:0000943
    label: Deep brain stimulation
  - id: HP:0002072
    label: Chorea
  - id: HP:0100033
    label: Tics
  - id: HP:0001336
    label: Myoclonus
  - id: HP:0033256
    label: pancolitis
  - id: MONDO:0002691
    label: liver cancer
  - id: MONDO:0000001
    label: diseases
